Skip to main content

Table 3 Severity of reaction by modified NCI scale

From: Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis

Grade 1A Cutaneous rash, flushing, generalised pruritus 5 (17.9%)
Grade 1B 1A plus, back pain and or HTN 2 (7.1%)
Grade 2 Urticaria, nausea/vomiting, throat tightness, Asymptomatic bronchospasm, chest tightness 3 (10.7%)
Grade 3 Symptomatic bronchospasm, dysponea, hypoxia, wheeze 7 (25%)
Grade 4 Anaphylaxis, hypotension 0
Grade 5 Death 1 (3.6%)
Unclassified due to lack of information available to stratify severity 4 (14.3%)
Delayed adverse event occurred after 48 h of infusion 6 (21.4%)